PLUS1
0.671
0.026 (4.03%)
0.026 (4.03%)
Upgrade to Real-Time
Regular Market
Best deals to access real time data! |
|
Ultimate Trader (Monthly)
Monthly Subscription
for only
|
|
Small Cap Basic
Monthly Subscription
for only
|
|
Big Cap Pro
Monthly Subscription
for only
|
|
VAT not included
|
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Outlook Therapeutics Inc | OTLK | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded  |
|
|---|---|---|---|---|
| 0.026 | 4.03% | 0.671 | 14:42:59 |
| Close Price | Low Price | High Price | Open Price | Previous Close |
|---|---|---|---|---|
| 0.6305 | 0.68 | 0.65 | 0.645 |
| Bid Price | Ask Price | Spread | News | |
|---|---|---|---|---|
| 0.671 | 0.6738 | 0.0029 | - | - |
| Stock Trades | Traded Volume | VWAP | Dollar Volume | Average Volume | 52 Week Range |
|---|---|---|---|---|---|
| 1,062 | 364,163 | $ 0.6598958 | $ 240,310 | 3,233,911 | 0.4011 - 1.74 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 14:46:08 | 50 | $ 0.671 | USD |
Outlook Therapeutics Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| $ 85.34M | 127.18M | 105.54M | $ 8.15M | $ - | -2.42 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | $ - | 0.00% | - | - |
Outlook Therapeutics News
| Date | Time | Source | News Article |
|---|---|---|---|
| 9/22/2020 | 17:15 | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) |
| 9/18/2020 | 17:17 | Edgar (US Regulatory) | Current Report Filing (8-k) |
| 9/17/2020 | 19:20 | Edgar (US Regulatory) | Amended Statement of Changes in Beneficial Ownership (4/a) |
| 9/17/2020 | 19:19 | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) |
| 9/15/2020 | 18:31 | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) |
| 9/08/2020 | 08:05 | GlobeNewswire Inc. | Outlook Therapeutics to Present at Two Upcoming Investor.. |
| 8/26/2020 | 08:11 | Edgar (US Regulatory) | Current Report Filing (8-k) |
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical OTLK Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 0.667 | 0.746 | 0.6305 | 0.686928 | 1,293,936 | 0.004 | 0.6% |
| 1 Month | 0.75 | 0.82 | 0.58 | 0.6693554 | 2,005,824 | -0.079 | -10.53% |
| 3 Months | 1.30 | 1.73 | 0.58 | 1.17 | 2,952,295 | -0.629 | -48.38% |
| 6 Months | 0.5417 | 1.73 | 0.51 | 1.15 | 2,268,375 | 0.1293 | 23.87% |
| 1 Year | 1.72 | 1.74 | 0.4011 | 1.11 | 1,479,624 | -1.05 | -60.99% |
| 3 Years | 5.60 | 20.00 | 0.4011 | 1.83 | 1,657,293 | -4.93 | -88.02% |
| 5 Years | 5.60 | 20.00 | 0.4011 | 1.83 | 1,657,293 | -4.93 | -88.02% |
Outlook Therapeutics Description
| Outlook Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. |
